You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An online professional development course to train CHWs to provide oral health outreach to low-income Black guardians

    SBC: KDH Research & Communication, Inc.            Topic: W

    KDH Research and Communication (KDHRC) submits this Phase II Small Business Innovation Research (SBIR) application to expand and fully evaluate Guardians Receiving Information through Navigators (GRIN). GRIN is a culturally competent, online professional development course to prepare community health workers (CHWs) to provide oral health outreach to low- income Black parents/guardians (henceforth ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a PIV5-based human metapneumovirus (HMPV) vaccine

    SBC: CYANVAC LLC            Topic: NIAID

    ABSTRACT In this Phase I SBIR application, we propose to develop an intranasal, parainfluenza virus 5 (PIV5)-based human metapneumovirus (HMPV) vaccine. HMPV is one of the leading causes of acute respiratory infections (ARIs) in children, immunocompromised individuals, and the elderly. Illness ranges from asymptomatic infection to severe bronchiolitis and pneumonia, with 90-100% of children infect ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Guidewire Design and Coating for Adenosine Delivery

    SBC: ADENOPAINT LLC            Topic: NHLBI

    Coronary artery disease (CAD) effects 14 million Americans resulting in approximately 900,000 myocardial infarction’s (MI) and 650,000 deaths annually. Percutaneous intervention (PCI) is the most frequently performed procedure to treat CAD. Microvascular obstruction (MVO) and “no reflow phenomenon” (NRF) are major barriers that preclude optimal outcomes and are independent risk factors for m ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Design and synthesis of a next generation glycobiology toolbox for cell surface labeling

    SBC: CHEMILY, LLC            Topic: 300

    The cell membrane is the interface by which a cell interacts and communicates with its surroundings, including nearby cells, proteins, and antibodies. Membranes of healthy cells are often modified in diseased states, providing an external means to distinguish between morphologically similar cells. Often, diseased cells display modified carbohydrates and glycans on their cell membranes. Recent deve ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma

    SBC: OncoSpherix, Inc.            Topic: 102

    Summary:The goal of this Phase II SBIR is to advance OncoSpherix’s HIF-1 inhibitor, 64B, as part of combination therapy for metastatic and high-risk uveal melanoma (UM), the most prevalent primary eye cancer in adults. 64B is a small molecule therapeutic that inhibits HIF function by disrupting the recruitment of the transcriptional co- factor, p300/CBP, while leaving intact p300/CBP’s ability ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization Readiness for Nerve Tape: a nerve repair coaptation aid

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: NINDS

    Project Summary This SBIR Commercialization Readiness Pilot project will prepare and achieve the commercial launch of Bio- Circuit Technologies’ Nerve Tape® device for sutureless nerve repair. Nerve injuries are common and result in paralysis, sensory loss, and chronic pain. In current repair techniques, the ends of a cut nerve are microsutured back together under high magnification by a specia ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Perfused organ panel as an animal surrogate for chemical toxicity testing

    SBC: LENA BIOSCIENCES, INC.            Topic: R

    This project responds to the NIEHS RFA-ES-20-005 “Organotypic culture models developed from experimental animals for chemical toxicity screening,” that is aligned with the needs of the NTP’s Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) for development and evaluation of new, revised, and alternative methods to identify potential hazards to human health ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Spinal Reflex Conditioning System for Enhancing Motor Function Recovery After Incomplete Spinal Cord Injury

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: 999

    Project Summary Spinal Cord Injury (SCI) affects ~300,000 people in the US, with 11,000 new cases/year. After SCI, spinal reflex function becomes abnormal, contributing to motor impairments and spasticity that affects 65-78% of people with SCI. Thus, restoring the function of spinal reflex pathways is a major therapeutic goal. Current therapies are only moderately successful; motor function often ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE)-a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)

    SBC: MMJ Labs, LLC            Topic: NIDA

    Project Summary This project will develop a Clinical Outcome Assessment (COA) for the FDA’s Medical Device Development Tool (MDDT) program assessing patient-reported outpatient opioid use, then calculating the gold standard metric of milligrams of morphine equivalents (MME) using the CDC MME Conversion dataset. In the qualified context of use of a clinical trial with informed consent to report a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. ADEPT-STAR therapy for high risk neuroblastoma

    SBC: EXPRESSION THERAPEUTICS, LLC            Topic: 100

    PROJECT SUMMARY Cancer remains a primary health concern despite significant advancements in treatment. In the past decade, cell and gene (CandG) therapies along with immuno-oncology (I-O) therapies have transformed treatment expectations by extending cancer free survival and complete remissions. Despite these remarkable successes, they are limited to a subset of cancers and many significant challe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government